Diagnostic Kit Maker Illumina To Cut $100 Million In Costs, Lowers 2025 Profit Outlook Amid China Trade Restrictions
Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for ...
Illumina price target lowered to $128 from $247 at RBC Capital
RBC Capital lowered the firm’s price target on Illumina (ILMN) to $128 from $247 but keeps an Outperform rating on the shares. The company’s ...
Illumina (ILMN) Gets a Buy from RBC Capital
In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Illumina (ILMN – Research Report), with a price ...
Illumina lowers guidance, cuts spending to mitigate China ban on its gene sequencers
Illumina lowered its adjusted profit outlook and cut spending cost for 2025 as the company grapples with Chinese ban on its ...
San Diego Union-Tribune10d
Illumina cuts workforce at San Diego headquarters
Gene-sequencing giant Illumina is laying off 96 employees from its San Diego headquarters, according to paperwork filed with the state. This workforce reduction comes at a time when Illumina is ...
San Diego Union-Tribune9d
China hits Illumina with import ban. What does that mean for the San Diego gene sequencer?
The Chinese government took its economic sanctions against San Diego-based Illumina a step further Tuesday by banning the gene-sequencing company from importing its machines to the country.
Benzinga.com9d
Demystifying Illumina: Insights From 11 Analyst Reviews
11 analysts have expressed a variety of opinions on Illumina ILMN over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments ...